Christopher Gibson - 16 Dec 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
16 Dec 2021
Transactions value $
-$4,001
Form type
4
Filing time
20 Dec 2021, 16:59:01 UTC
Previous filing
15 Dec 2021
Next filing
14 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Conversion of derivative security $0 +200 +0.85% $0.00 23.7K 16 Dec 2021 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$4K -200 -0.84% $20.01* 23.5K 16 Dec 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -200 0% $0.00 8.19M 16 Dec 2021 Class A Common Stock 200 $0.00 Direct F1, F2, F4
holding RXRX Stock Option (Right to Buy) 1.47M 16 Dec 2021 Class A Common Stock 1.47M $2.47 Direct F5
holding RXRX Class B Common Stock 550K 16 Dec 2021 Class A Common Stock 550K $0.00 by LAHRAWN-3 LLC F4, F6
holding RXRX Class B Common Stock 550K 16 Dec 2021 Class A Common Stock 550K $0.00 by LAHRAWN-4 LLC F4, F7
holding RXRX Class B Common Stock 147K 16 Dec 2021 Class A Common Stock 147K $0.00 by Gibson Family Trust F4, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Represents the conversion of Class B Common Stock into Class A Common Stock.
F3 This transaction was executed in multiple trades at prices ranging from $20.00 to $20.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F5 The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F7 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F8 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.